-
1
-
-
0035011978
-
In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers
-
Fuchs P.C., Barry A.L., Brown S.D. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:2001;1915-1918.
-
(2001)
Antimicrob. Agents Chemother.
, vol.45
, pp. 1915-1918
-
-
Fuchs, P.C.1
Barry, A.L.2
Brown, S.D.3
-
2
-
-
0036277197
-
Use of surrogate antimicrobial agents to predict susceptibility to ertapenem
-
Friedland I., Isaacs R., Mixson L.A., Motyl M., Woods G.L. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem. Diagn. Microbiol. Infect. Dis. 43:2002;61-64.
-
(2002)
Diagn. Microbiol. Infect. Dis.
, vol.43
, pp. 61-64
-
-
Friedland, I.1
Isaacs, R.2
Mixson, L.A.3
Motyl, M.4
Woods, G.L.5
-
3
-
-
0036604093
-
Once a day ertapenem versus four daily doses of piperacillin-tazobactam for treatment of complicated skin and skin structure infections in adults: Results of a prospective, randomized, double-blind multicenter study
-
Graham D., Lucasti C., Malafaia O.et al. Once a day ertapenem versus four daily doses of piperacillin-tazobactam for treatment of complicated skin and skin structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin. Infect. Dis. 34:2002;1460-1468.
-
(2002)
Clin. Infect. Dis.
, vol.34
, pp. 1460-1468
-
-
Graham, D.1
Lucasti, C.2
Malafaia, O.3
-
4
-
-
0037648561
-
Ertapenem once a day versus piperacillin-tazobactam every 6 h for treatment of acute pelvic infections: A prospective, multicenter, randomized double-blind study
-
Roy S., Higareda I., Angel-Muller E.et al. Ertapenem once a day versus piperacillin-tazobactam every 6 h for treatment of acute pelvic infections: a prospective, multicenter, randomized double-blind study. Infect. Dis. Obstet. Gynecol. 11:2003;1-11.
-
(2003)
Infect. Dis. Obstet. Gynecol.
, vol.11
, pp. 1-11
-
-
Roy, S.1
Higareda, I.2
Angel-Muller, E.3
-
5
-
-
0037315316
-
Results of a double-blind, randomized comparative phase III trial of ertapenem vs. piperacillin/tazobactam for treatment of complicated intraabdominal infections
-
Solomkin J.S., Choe K.A., Rotstein O.D.et al. Results of a double-blind, randomized comparative phase III trial of ertapenem vs. piperacillin/tazobactam for treatment of complicated intraabdominal infections. Ann. Surg. 237:2003;235-245.
-
(2003)
Ann. Surg.
, vol.237
, pp. 235-245
-
-
Solomkin, J.S.1
Choe, K.A.2
Rotstein, O.D.3
-
6
-
-
0037090185
-
A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults
-
Ortiz-Ruiz G., Caballero-Lopez J., Friedland I., Woods G.L., Carides A. the Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin. Infect. Dis. 34:2002;1076-1083.
-
(2002)
Clin. Infect. Dis.
, vol.34
, pp. 1076-1083
-
-
Ortiz-Ruiz, G.1
Caballero-Lopez, J.2
Friedland, I.3
Woods, G.L.4
Carides, A.5
-
7
-
-
0036292299
-
A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults
-
Jimenez-Cruz F., Jasovich A., Cajigas J.et al. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults. Urology. 60:2002;16-22.
-
(2002)
Urology
, vol.60
, pp. 16-22
-
-
Jimenez-Cruz, F.1
Jasovich, A.2
Cajigas, J.3
-
8
-
-
0032802191
-
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin, or vancomycin
-
Nichols R.L., Graham D.R., Barriere S.L.et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin, or vancomycin. J. Antimicrob. Chemother. 44:1999;263-273.
-
(1999)
J. Antimicrob. Chemother.
, vol.44
, pp. 263-273
-
-
Nichols, R.L.1
Graham, D.R.2
Barriere, S.L.3
-
9
-
-
0032867146
-
Optimal treatment of complicated skin and skin structure infections
-
Nichols R.L. Optimal treatment of complicated skin and skin structure infections. J. Antimicrob. Chemother. 4:1999;19-23.
-
(1999)
J. Antimicrob. Chemother.
, vol.4
, pp. 19-23
-
-
Nichols, R.L.1
-
10
-
-
0027326250
-
Treatment of hospitalized patients with complicated skin and skin structure infections: Double-blind randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate
-
Tan J.S., Wishnow R.M., Taklan D.A., Duncanson E.F., Norden C.W. the Piperacillin/Tazobactam Skin and Skin Structure Study Group Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrob. Agents Chemother. 37:1993;1580-1586.
-
(1993)
Antimicrob. Agents Chemother.
, vol.37
, pp. 1580-1586
-
-
Tan, J.S.1
Wishnow, R.M.2
Taklan, D.A.3
Duncanson, E.F.4
Norden, C.W.5
-
11
-
-
0035145047
-
Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections
-
Siami G., Christou N., Eiseman I., Tack K.J. the clinafloxacin severe skin and soft tissue infections study group Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob. Agents. Chemother. 45:2001;525-531.
-
(2001)
Antimicrob. Agents. Chemother.
, vol.45
, pp. 525-531
-
-
Siami, G.1
Christou, N.2
Eiseman, I.3
Tack, K.J.4
-
12
-
-
0037102954
-
Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: A randomized, open-label trial
-
Graham D.R., Talan D.A., Nichols R.L.et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin. Infect. Dis. 35:2002;381-389.
-
(2002)
Clin. Infect. Dis.
, vol.35
, pp. 381-389
-
-
Graham, D.R.1
Talan, D.A.2
Nichols, R.L.3
-
13
-
-
0026492838
-
General guidelines for the clinical evaluation of anti-infective drug products
-
Beam T.R. Jr., Gilbert D.N., Kunin C.M. General guidelines for the clinical evaluation of anti-infective drug products. Clin. Infect. Dis. 15:1992;S5-32.
-
(1992)
Clin. Infect. Dis.
, vol.15
, pp. 5-32
-
-
Beam, T.R.Jr.1
Gilbert, D.N.2
Kunin, C.M.3
-
14
-
-
0003655628
-
-
NCCLS document M2-A6. Wayne, PA: National Committee for Clinical Laboratory Standards;
-
National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests: approved standard. NCCLS document M2-A6. Wayne, PA: National Committee for Clinical Laboratory Standards; 1997.
-
(1997)
Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard
-
-
|